| Literature DB >> 30306067 |
Yi Li1, Xiaosong Xu1, Xiaopeng Tang1, Xiuwu Bian2, Bingbing Shen1, Hongwen Zhao1, Shiyuan Luo1, Zhiwen Chen3, Keqin Zhang1.
Abstract
BACKGROUND: Type IV lupus nephritis (LNIV) is a severe disease characterized by diffuse proliferative lesions, and its prognosis is worse with cellular crescent (LNIV-CC) involvement. Urinary exosomes have been shown to reflect the degree of kidney injury. This study was aimed to identify non-invasive diagnostic markers for LNIV-CC. We analysed the expression profile of microRNAs (miRNAs) isolated from urinary exosomes in patients with LNIV-CC and LNIV, and healthy individuals using high-throughput sequencing.Entities:
Keywords: High-throughput sequencing; Type IV lupus nephritis; Urinary exosome; miRNAs
Year: 2018 PMID: 30306067 PMCID: PMC6172751 DOI: 10.1186/s40709-018-0088-0
Source DB: PubMed Journal: J Biol Res (Thessalon) ISSN: 1790-045X Impact factor: 1.889
Baseline clinical data of the screening groups (mean ± SD)
| Characteristic | Active LNIV-CC (n = 5) | Active LNIV (n = 5) | Inactive LNIV (n = 4) | Healthy controls (n = 3) |
|---|---|---|---|---|
| Age | 24.6 ± 10.71 | 27.8 ± 12.50 | 28 ± 15.79 | 39.67 ± 10.66 |
| Gender | Female | Female | Female | Female |
| eGFR (ml min−1 1.73 m−2) | 91.85 ± 14.77 | 96.20 ± 12.78 | 110.55 ± 5.69 | 121.3 ± 13.33 |
| Proteinuria (mg day−1) | 1819 ± 973.69a,b | 4080.4 ± 1878.75a | 220.33 ± 178.01 | |
| SLEDAI | 12.2 ± 1.79a | 13.4 ± 4.22a | 2 ± 1.63 | |
| C3 (mg dl−1) | 0.44 ± 0.10 | 0.37 ± 0.25 | 0.58 ± 0.37 | |
| C4 (mg dl−1) | 0.08 ± 0.03 | 0.07 ± 0.05 | 0.14 ± 0.10 | |
| Cr (mg dl−1) | 2.11 ± 0.74 | 1.02 ± 0.51 | 0.73 ± 0.23 | 0.60 ± 0.1 |
Cr, creatine; eGFR, estimated glomerular filtration rate; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index
ap < 0.01 compared to inactive LNIV
bp < 0.05 compared to active LNIV without cellular crescents
Fig. 1Characteristics of urinary exosomes. a Transmission electron microscope images of isolated exosomes. Bars = 100 nm. Diameter of the exosome measured at 74.66 nm. b Western blot indicated CD9 and CD81-positive expression and calnexin-negative expression
Fig. 2Heatmaps of differentially expressed miRNAs (p < 0.05) between LNIV-CC and control groups
Fig. 3Volcano plots of differentially expressed miRNAs (p < 0.05) between LNIV-CC and control groups
Fig. 4Heatmaps of differentially expressed miRNAs (p < 0.05) between LNIV-CC and LNIV (active) groups
Fig. 5Volcano plots of differentially expressed miRNAs (p < 0.05) between LNIV-CC and LNIV (active) groups
Fig. 6Expression of selected exosomal miRNAs for each group. Each value represents the mean ± SEM; *p < 0.05, ***p < 0.001 compared with control
Fifteen signalling pathways affected in LVIN-CC
| KEGG pathway | N genes | N miRNAs | |
|---|---|---|---|
| Wnt signalling pathway | 0.00020396 | 100 | 59 |
| Signalling pathways regulating pluripotency of stem cells | 0.001959962 | 95 | 57 |
| Focal adhesion | 0.002590298 | 138 | 56 |
| Hippo signalling pathway | 3.53E−05 | 107 | 54 |
| Neurotrophin signalling pathway | 0.009351432 | 81 | 54 |
| Axon guidance | 1.45E−05 | 94 | 52 |
| FoxO signalling pathway | 0.00541505 | 92 | 52 |
| Ubiquitin-mediated proteolysis | 0.006921462 | 91 | 49 |
| ErbB signalling pathway | 0.000164182 | 67 | 49 |
| TGF-beta signalling pathway | 0.004491223 | 53 | 48 |
| Arrhythmogenic right ventricular cardiomyopathy | 0.00042872 | 51 | 46 |
| Lysine degradation | 0.00109878 | 34 | 46 |
| N-Glycan biosynthesis | 0.009852971 | 34 | 39 |
| Other types of O-glycan biosynthesis | 0.034708487 | 20 | 32 |
| Fatty acid biosynthesis | 3.53E−05 | 8 | 11 |
These pathways were identified from the intersection of the DIANA-mirPath results of three databases (TargetScan, Tarbase7.0, and microT-CDS v5.0) with exclusion of tumour, hepatitis B, leukaemia, and thyroid hormone-related pathways
Fig. 7Network interactions between miRNAs, TFs, and target genes. The red circular nodes are miRNAs, the blue circular nodes are miRNA gene targets, and the green nodes are TFs. The grey line connects with down-regulated miRNAs, and the purple line connects with up-regulated miRNAs
Fig. 8ROC curve for the validated miRNAs